Doctors work inside the intensive care unit for people infected with the new coronavirus, at a hospital in Moscow, Russia. File picture: Sophia Sandurskay/AP
Doctors work inside the intensive care unit for people infected with the new coronavirus, at a hospital in Moscow, Russia. File picture: Sophia Sandurskay/AP

Russian institute claims success in human trial of Covid-19 vaccine

By Reuters Time of article published Jul 13, 2020

Share this article:

Moscow - A Russian institute developing

one of the country's potential coronavirus vaccines hopes to

start its final stage testing in a small section of the general

public in mid-August, the RIA news agency cited the institute's

director as saying on Monday.

Globally, of 19 experimental Covid-19 vaccines in human

trials, only two are in final Phase III trials - one by China's

Sinopharm and another by AstraZeneca and the University

of Oxford. China's Sinovac Biotech is set to become the

third later this month.

Early results from the first small-scale human trial of the

vaccine developed by the Gamaleya Institute in Moscow has shown

it to be safe for use, according to a separate RIA report on

Sunday.

"Around 14-15 August, I hope, the small amount of vaccine

that we should be able to produce will enter public

circulation," Alexander Ginsburg, the institute's director, was

quoted as saying.

This will be equivalent to a Phase III trial, since people

getting the vaccine will remain under supervision, RIA reported,

citing Ginsburg.

Phase I and Phase II trials typically test the safety of a

drug before it enters Phase III trials that test its efficacy on

a bigger group of volunteers.

Human trials of the Gamaleya Institute's vaccine began on

June 18, with nine volunteers receiving one dose, and another

nine testing the prospective booster dose.

The group did not experience any significant side effects

and is due to be released from hospital on Wednesday, RIA

reported on Sunday, citing a director at the Sechenov University

in Moscow where the trial took place.

"Data currently available... shows the volunteers to have

developed an immune response to the coronavirus vaccine," the

defence ministry, involved in the trials, was cited by RIA as

saying on Monday. Another 20 volunteers were administered the

vaccine at a military hospital on June 23. 

Reuters

Share this article: